Table 1. Main results of the selected studies.

EMT-TF	Author (Ref.)	Year	SS	PA	Pop.	TNM	TFP (%)	FT (M)
TWIST1	Fu J. et al.13	2012	28	ab 50887, Abcam, UK	CN	ΙΙΙ C	61	NR
	van Nes et al.19	2012	575	ab5088, Abcam, UK	NL	ΙΙΙ B	50	240
	Vesuna F. et al.20	2008	87	Abcam, UK	NL	ΙΙΙ B	65	NR
	Montserrat N. et al.21	2011	76	–	ES	ΙΙΙ B	29	200
	Watanabe O. et al.22	2004	23	Santa Cruz, CA, USA	JP	Ш B/C	69.6	NR
SNAIL1	Yang Z. et al.23	2015	125	Abcam, UK	CN	ΙΙΙ B	38.4	120
	Muenst S. et al.25	2013	1043	Santa Cruz, CA, USA	CH	ΙΙΙ B	49.4	120
	Zhang A. et al.26	2013	60	Santa Cruz, CA, USA	CN	Ш C/IV	47	NR
	Mimoto R. et al.27	2013	61	Abcam, UK	JP	Ш C	47.6	120
	van Nes. et al.19	2012	575	ab27568, Abcam, UK	NL	Ш B	54.5	240
	Joensuu K. et al.24	2011	73	ab17732, Abcam, UK	FI	ΙΙΙ B	75	NR
	Montserrat N. et al.21	2011	75	–	ES	ΙΙΙ B	29	200
	Lundgren K. et al.31	2009	500	CST, Beverly, MA, USA	SE	ΙΙΙ A	23.7	240
ZEB1	Arima Y. et al.28	2012	14	Vector Lab, CA, USA	JP	ΙΙΙ A/B	45	NR
	Montserrat N. et al.21	2011	75	–	ES	ΙΙΙ B	19	200
SLUG	Liu T. et al.29	2013	441	Abcam, UK	CN	ΙΙΙ C	61	60
	Wu G. et al.30	2012	113	CST, Beverly, MA, USA	CN	ΙΙΙ C	44	NR

Abbreviations: EMT-TFs, EMT-inducing transcription factors; SS, sample size; PA, primary antibody used for IHC; Pop., populations; TNM, tumor-node-metastasis; TFP, EMT-TF positive; FT, flow time; M, months; NR, not reported.